

Datasheet: HCA265

| | |
|----------------------|------------------------|
| Description: | HUMAN ANTI PANITUMUMAB |
| Specificity: | PANITUMUMAB |
| Other names: | VECTIBIX® |
| Format: | Purified |
| Product Type: | Monoclonal Antibody |
| Clone: | AbD23897_hIgG1 |
| Isotype: | IgG1 |
| Quantity: | 0.1 mg |

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

| | Yes | No | Not Determined | Suggested Dilution |
|-------|-----|----|----------------|--------------------|
| ELISA | ■ | | | |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

| | |
|---------------------------------------|---|
| Product Form | Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. |
| Preparation | Purified IgG prepared by affinity chromatography on Protein A |
| Buffer Solution | Phosphate buffered saline |
| Preservative Stabilisers | 0.01% Thiomersal |
| Approx. Protein Concentrations | IgG concentration 0.5 mg/ml |
| Immunogen | Panitumumab |

Specificity

Human anti panitumumab, clone AbD23897_hIgG1, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the fully human monoclonal antibody drug panitumumab and inhibits it binding to its target, epidermal growth factor receptor (EGFR). The antibody can be used to measure the levels of panitumumab and biosimilar products in bioanalytical assays.

Clone AbD23897_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. Additionally the antibody

can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in full immunoglobulin format, is recommended as the detection antibody, paired with the antibody clone AbD23894 ([HCA264](#)) in monovalent Fab format, as the capture antibody.

Panitumumab (Vectibix®) is a fully human monoclonal antibody (IgG2/kappa) specific to the transmembrane protein EGFR. The drug binds to the extracellular domain of the EGFR, inhibiting the activation of the intracellular signaling cascade. It is approved by the FDA and EMA for the treatment of EGFR-expressing metastatic colorectal cancer.

[View a summary of all anti panitumumab antibodies](#)

| | |
|--------------------------------------|---|
| Affinity | The monovalent intrinsic affinity of this antibody was measured as $K_D = 0.3$ nM by real time, label free molecular interaction analysis on immobilized panitumumab. |
| ELISA | This product may be used in direct or indirect ELISA and in an ELISA bridging assay as a detection antibody together, when conjugated to HRP, with HCA264 as the capture reagent. It is also suitable as a fully human control or calibrator antibody in an ADA bridging ELISA. Protocol: PK bridging ELISA to measure free drug Protocol: ADA bridging ELISA |
| References | 1. Kashiwagi, N. <i>et al.</i> (2017) Method for measuring anti-drug antibody US Patent Application US20170315118A1 |
| Storage | Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. |
| Guarantee | 12 months from date of despatch |
| Acknowledgements | Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. |
| Health And Safety Information | Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf |
| Licensed Use | For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad. |
| Regulatory | For research purposes only |
| Technical Advice | Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual |

Related Products

Recommended Useful Reagents

[HUMAN ANTI PANITUMUMAB \(HCA264\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

HUMAN ANTI PANITUMUMAB (HCA266)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

'M371698:200612'

Printed on 11 Aug 2020

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)